Text Size

Prospective Controlled Study of Posttransplant Diabetes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2003 by National Center for Research Resources (NCRR).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:
NCT00006331
First received: October 4, 2000
Last updated: June 27, 2005
Last verified: December 2003
History of Changes
  Purpose

Research participants will be asked to undergo complete medical history, physical examination and blood tests. The purpose of these tests is to determine whether persons are predisposed to develop diabetes mellitus after kidney transplantation and also to make an early diagnosis if a patient develops diabetes mellitus. Medical information collected as part of the standard transplant evaluation and posttransplant medical care may be incorporated into this study. It is important to realize that research subjects will not be given an experimental drug as part of this study.

After kidney transplantation, research subjects will be followed in the posttransplant clinic visits. The study will last up to 6 months. During this time the subjects may be asked to participate in clinical assessment visits (medical history and physical examination), and also during the third or fourth month after transplant will be asked to do a repeat glucose tolerance test.


Condition Intervention
Diabetes Mellitus
Kidney Failure
 Procedure: renal transplant

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Center for Research Resources (NCRR):

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fasting Plasma Glucose (FPG) <126mg/dl.
  • No history of diabetes mellitus or treatment with oral antidiabetic agent or insulin.
  • ESRD or chronic renal failure with CrCl <= 20cc/min per 1.73m2.
  • Waiting list registration for cadaveric or set date for living donor renal transplantation.
  • Willingness and ability to understand and give informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006331

Contacts
Contact: Akinlolu O. Ojo, M.D., Ph.D. 1-734-763-9041 aojo@umich.edu

Locations
United States, Michigan
3914 Taubman Center Recruiting
Ann Arbor, Michigan, United States, 48109-0364
Contact: Akinlolu O. Ojo, M.D.     734-763-9041     aojo@umich.edu    
Sponsors and Collaborators
National Center for Research Resources (NCRR)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00006331     History of Changes
Other Study ID Numbers: NCRR-M01RR00042-1699, M01RR00042
Study First Received: October 4, 2000
Last Updated: June 27, 2005
Health Authority: United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):
Kidney transplantation
Immunology

Additional relevant MeSH terms:
Diabetes Mellitus
Renal Insufficiency
Glucose Metabolism Disorders
Metabolic Diseases
 Endocrine System Diseases
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 23, 2013